Injongo yocwaningo

Leli yiqembu elilodwa, elebula elivulekile, ucwaningo lwezindawo eziningi kubahlanganyeli bezingane abanokutheleleka kwe-human immunodeficiency virus uhlobo 1 (HIV-1), abanobudala bamaviki angu-4 kuya <iminyaka engu-12 futhi banesisindo esingu-<45 kg, aba-treatment-naive (TN) noma aba-virologically suppressed (VS) enhlanganiselele ezinzile yokwelapha kwe-antiretroviral (cART) izinyanga ezi-≥3 abangenawo umlando wokwehluleka ukwelashwa. Inhloso yokuqala eyinhloko ukuhlola isimo esizinzile se-pharmacokinetics (PK) ye-doravirine (DOR) [MK-1439] lapho inikezwa kuhlanganiswe ne-6 nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs) noma njengengxenye yenhlanganisela yomthamo ongaguquki (FDC) we-DOR/lamivudine (3TC)/tenofovir disproxil fumarate (TDF) kubambiqhaza abaneminyaka eyi-≥12 kuya ku-<14 futhi abanesisindo ≥45 to <45 kg. Inhloso yesibili eyinhloko ukuhlola ukuphepha nokubekezelelana kwe-DOR uma inikezwa nama-NRTI angu-2 noma njengengxenye ye-FDC ye-DOR/3TC/TDF, kubahlanganyeli abaneminyaka eyi-≥6 kuya kwengu 12 futhi abanesisindo esi-≥14 kuya ku-<45 kg, ukufika Evikini 24.

Isihlonzi se- Clinicaltrials.gov

I-NCT04375800

I-EudraCT

2019-003955-13

Lapho uxoxa nodokotela wakho noma ilungu leqembu locwaningo lwezokwelapha, sicela ube nenombolo yereferensi yocwaningo noma inombolo ye-EudraCT.

Izinsiza

Ukufaneleka

Uchwepheshe wezempilo uyena kuphela onganquma ukuthi uyafaneleka yini ukubamba iqhaza ocwaningweni lwezokwelapha. Nokho, lolu lwazi lungaba usizo ekuqaleni ingxoxo nodokotela wakho.

Izimo Icon

Izimo

HIV, Ku-Human Immunodeficiency Virus

Ububanzi Bobudala Icon

Ububanzi Bobudala

4 - 11

Ubulili Icon

Ubulili

Konke

Trial phase Icon Isigaba socwaningo esiqhubekayo

Isigaba ISIGABA2 Socwaningo

Ezingcwaningweni Zesigaba 2, abacwaningi bazama ukuthola ukuthi umuthi ungasebenza yini kubabambiqhaza abayi-100 ukuya ku-500 – ngokuvamile abantu abanesimo sempilo esizokwelashwa umuthi. Ezingcwaningweni zomgomo, ababambiqhaza ngokuvamile abantu abanempilo. Izingcwaningo Zesigaba 2 zingeziwa ehhovisi lodokotela, emtholampilo, noma esibhedlela.

Trial start Icon Izinsuku zokuqala nokuqedwa kocwaningo
  • Usuku lokuqala kocwaningo Februwari 3, 2021
  • Usuku oluyinhloko lokuqeda olulinganiselwe Mashi 4, 2028
  • Usuku lokuqeda ucwaningo olulinganiselwe Ephreli 11, 2034

Izindawo zocwaningo

Izindawo ezibonisiwe kungenzeka zishintshile kwezinye izimo. Sicela ushayele inombolo esohlwini lwemiphumela yendawo ukuqinisekisa isikhungo socwaningo esiseduze. Xoxa nelungu lesikhungo socwaningo ukuthola ulwazi olwengeziwe.

Yikuphi ongakwenza ngokulandelayo?

Uma ucabanga ukuthi lolucwaningo lwezokwelapha lungakulungela futhi unesithakazela sokubamba iqhaza, ukuthatha isinyathelo esilandelayo ukuze ubone ukuthi uyafaneleka yini.

Xoxa nodokotela wakho noma iqembu lokunakekela

Phrintha leli khasi elinemininingwane yocwaningo noma ulithumele nge-imeyili kudokotela wakho ukuxoxa ngocwaningo lwezokwelapha ekuvakasheni okulandelayo.

Thola usizo ngokuxoxa nodokotela wakho noma iqembu lokunakekela

Isihlonzi se- Clinicaltrials.gov

I-NCT04375800

I-EudraCT

2019-003955-13

Lapho uxoxa nodokotela wakho noma ilungu leqembu locwaningo lwezokwelapha, sicela ube nenombolo yereferensi yocwaningo noma inombolo ye-EudraCT.

Ukubamba iqhaza ocwaningweni lwezokwelapha kuyisinqumo esibalulekile

Uma ucabangela ukujoyina ucwaningo lwezokwelapha, qala ngokufunda okuningi ngokunokwenzeka ngalo:

  • Umuthi wophenyo ocwaningwayo
  • Yiziphi izingozi noma izinzuzo ezingaba khona zababambiqhaza

Xoxa nodokotela wakho ngocwaningo lwezokwelapha ungakenzi isinqumo sokujoyina.

Funda ikhasi elithi “Ongakucabangela” ukuthola imibuzo eyengeziwe ongayibuza nongacabanga ngayo